ACC 2024

REDUCE-AMI trial suggests long-term beta-blocker treatment may not be necessary for patients with an acute myocardial infarction and preserved left ventricular ejection fraction.

Ticagrelor monotherapy is associated with a reduced risk for bleeding in patients with ACS after PCI than those receiving ticagrelor plus aspirin.

A self-expanding supra-annular valve outperforms a balloon-expandable valve in patients with aortic stenosis and a small aortic annulus undergoing TAVR.

Young adults who are prescribed stimulant medications to treat ADHD may be more likely to develop cardiomyopathy although incidence is low.

Treatment with empagliflozin may be useful in reducing hospitalization due to heart failure, but not all-cause mortality, after myocardial infarction.

A telemonitoring program for patients who received PCI for acute coronary syndrome and myocardial infarction or unstable angina reduced hospitalizations after 6-months.

Zilebesiran, combined with other antihypertensive therapy, significantly reduces 24-hour blood pressure after 6-months of treatment. 

A cohort analysis finds a decrease in infant mortality in the USA from congenital heart disease over the past two decades.

Those who smoke e-cigarettes are more likely to develop heart failure, particularly HFpEF, than who have not vaped before.

AI models may be able to accurately detect cardiac amyloidosis in a range of diagnostic examinations. 

Patients treated with icosapent-ethyl in the REDUCE-IT trial had fewer major adverse cardiovascular events.

An analysis using AI finds that those who can see the sidewalk, trees and sky from their home have a lower risk of heart disease.